

## **ACT BIOTECH Announces Treatment of First Gastric Cancer Patients with Telatinib in a Phase 2 Clinical Trial in the U.S. and Spain**

SAN FRANCISCO--July 30, 2009--ACT Biotech Inc., a privately held biotechnology company developing a portfolio of best-in-class oral kinase inhibitors as anti-cancer drugs, today announced the treatment of the first patients in a Phase 2 clinical trial of Telatinib in combination with standard-of-care chemotherapy for the treatment of gastric cancer. The Phase 2 multi-center trial is being conducted in the U.S. and in Spain with Principal Investigators at the University of Texas MD Anderson Cancer Center in Houston, Texas and the Vall d'Hebron University Hospital in Barcelona, Spain.

"We view Telatinib as the ideal anti-angiogenic drug for combination with chemotherapy to treat gastric cancer patients who are at an advanced disease stage. Due to its potent activity and outstanding safety profile we expect Telatinib to set a new standard of care for gastric cancer in combination with chemotherapy," said Wolf D. Busse Ph.D., Chief Executive Officer of ACT Biotech.

Telatinib is a potent small molecule oral kinase inhibitor targeting all the VEGFR family and PDGFR receptor tyrosine kinases. Telatinib has shown exquisite target selectivity in biochemical tests and strong efficacy in large Phase 1 clinical trials enrolling 250 patients. In these trials, treatment with Telatinib resulted in dramatic benefit including objective responses and a high rate of durable disease stabilization, particularly in patients with gastrointestinal (including gastric, colorectal and hepatocellular) or renal cancers. In addition, when combined with different chemotherapy regimens in Phase 1b clinical trials (XELIRI, FOLFOX or docetaxel), the full dose of Telatinib was well tolerated, did not contribute additional side effects and resulted in significant patient benefit. "Telatinib is a promising oral drug of the well-established class of angiogenesis inhibitors to treat patients with gastric or gastroesophageal adenocarcinomas. This combination of Telatinib with chemotherapy may prove to be more efficacious than the current standard-of-care chemotherapy," said Jaffer Ajani M.D., University of Texas MD Anderson Cancer Center, Houston, Texas.

Dr. Josep Tabertero of the Vall d'Hebron University Hospital in Barcelona, Spain added, "Based on early stage clinical results, we see a lot of promise for this drug candidate in treating our gastric cancer patients. The drug seems to combine with chemotherapy very well, shifting the balance towards better efficacy without additional toxicity."

The current Telatinib Phase 2 clinical program is designed to demonstrate the drug's effectiveness in treating advanced stage gastric cancer patients as measured by median progression-free survival. ACT Biotech plans to advance Telatinib in clinical trials in preparation for pivotal Phase 3 clinical trials in this indication. In addition, the Company plans to develop Telatinib in parallel for the treatment of colorectal cancer patients.

**About ACT Biotech, Inc**

ACT Biotech ([www.actbiotech.com](http://www.actbiotech.com)) is a San Francisco-based, privately-held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs. The Company's clinical stage pipeline also includes Telatinib, the most selective oral VEGF/PDGFR/KIT inhibitor ever developed. Telatinib is currently being studied in a Phase 2 trial for the first-line treatment of gastric cancer in combination with standard-of-care chemotherapy. An abstract based on preliminary results has been submitted to ASCO 2010 and a Phase 3 trial in first line gastric cancer is planned for late in 2010. Other programs at ACT Biotech include a novel Pan-Aurora kinase inhibitor at the pre-IND stage and a Bcr/Abl discovery program. ACT Biotech will be presenting at the BioPartnering North America conference in Vancouver, BC January 24<sup>th</sup> - 26<sup>th</sup> 2010. ACT Biotech is backed by NGN Capital of New York, NY; Greenwich, CT; and Heidelberg, Germany.

**Contact:**

Robert Jacks, VP Corporate Development

[robert.jacks@actbiotech.com](mailto:robert.jacks@actbiotech.com)

415-230-3907

#####